IN8bio (NASDAQ:INAB) Receives Buy Rating from HC Wainwright

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $8.00 price target on the stock.

IN8bio Trading Up 11.1 %

Shares of INAB stock opened at $0.32 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84. The firm has a market cap of $23.42 million, a PE ratio of -0.43 and a beta of 0.05. The company has a 50-day moving average of $0.28 and a two-hundred day moving average of $0.36. IN8bio has a 1-year low of $0.22 and a 1-year high of $1.74.

IN8bio (NASDAQ:INAB) last announced its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, analysts predict that IN8bio will post -0.56 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of IN8bio by 56.5% in the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after purchasing an additional 185,919 shares during the period. Franklin Resources Inc. purchased a new position in shares of IN8bio in the fourth quarter valued at approximately $1,465,000. AIGH Capital Management LLC boosted its stake in shares of IN8bio by 269.7% in the fourth quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock valued at $1,593,000 after purchasing an additional 4,517,227 shares during the period. BIOS Capital Management LP purchased a new position in shares of IN8bio in the fourth quarter valued at approximately $2,212,000. Finally, Sigma Planning Corp boosted its stake in shares of IN8bio by 22.3% in the fourth quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock valued at $268,000 after purchasing an additional 190,100 shares during the period. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.